Phio Pharmaceuticals Corp SEC Filings

Phio Pharmaceuticals (PHIO) reporting person Lisa C. Carson, who is listed as a director and VP, Finance and Administration, reported a non-derivative acquisition on 09/11/2025. The filing shows 47,000 shares of common stock were acquired at $0, representing shares underlying a restricted stock unit grant. The filing states those shares "will vest on the first annual anniversary of the grant," and that the 47,000 shares reported include common stock underlying unvested restricted stock units. The form is signed 09/15/2025.

Phio Pharmaceuticals Corp. director Patricia A. Bradford reported a change in beneficial ownership related to restricted stock units. The filing shows an acquisition of 18,800 shares of common stock issued to satisfy restricted stock units that will vest on the first annual anniversary of the grant. Following the reported transaction, Ms. Bradford beneficially owns 27,151 shares, a total that the filing indicates includes shares underlying unvested restricted stock units. The reported share counts have been adjusted to reflect prior reverse stock splits. The transaction was reported as an acquisition at $0 per share, consistent with issuance upon vesting of RSUs.

Robert J. Bitterman, Chairman, President and CEO of Phio Pharmaceuticals Corp. (PHIO), reported equity transactions on a Form 4 filed for activity dated 09/11/2025. The filing shows 4,111 shares were withheld by the issuer to satisfy tax withholding related to vested restricted stock units; no shares were sold.

The reporting person was also granted 250,000 restricted stock units on that date that vest on the first annual anniversary of the grant. After these transactions the filing reports 271,421 shares of common stock beneficially owned by Mr. Bitterman. The Form 4 was signed by an attorney-in-fact on 09/15/2025.

Phio Pharmaceuticals Corp. (PHIO) reported interim financials showing continued operating losses and active financing and warrant activity. The company recorded an operating loss of $2,309 and a net loss of $2,166 for the most recent quarter presented, compared with operating loss of $1,914 and net loss of $1,846 in the prior period. Cash flows show a net increase in cash of $5,393 for the period and modest investing outflows.

The filing discloses multiple financings and warrant issuances: net proceeds of approximately $2.646 million from a July 2024 financing, and subsequent registered direct and private placements in January 2025 generating approximately $2.9M, $2.2M, $1.6M and other raises. The company completed a 1-for-9 reverse stock split and recorded significant non-cash equity issuance costs (about $2.4M for warrant fair value and ~$0.2M placement agent warrants). Clinical and collaboration expenses include $4,000,000 incurred for a Phase 1 trial of PH-762. The report lists customary risk factors, reliance on third parties, and material uncertainty around future capital needs.

Phio Pharmaceuticals Corp. (PHIO) filed a Form D announcing a Rule 506(b) private placement that opened 28-Jul-2025.

• Target size: up to $5.08 million in warrants and the underlying common shares.
• Raised to date: $232,149 (≈4.6% of target) from two accredited investors; minimum investment $0.
• Remaining to sell: $4.85 million.
• Broker compensation: $261,753 cash (≈5.2% of capital raised) plus 69,645 warrants (7,500 exercisable at $2.8125; 62,145 at $3.4188).
• Securities offered: options/warrants and the shares issuable upon exercise; no debt or pooled-fund interests.
• Offering duration: expected to close within one year; not linked to a business combination.
• Issuer profile: Delaware-incorporated biotechnology company headquartered in King of Prussia, PA; revenue size undisclosed.

No proceeds are slated for payments to directors, officers or promoters. Reliance on Reg D limits the sale to accredited investors and keeps detailed financials private. Execution risk remains until the full amount is subscribed.